Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 3/20 | 0.66 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CCR3 | P51677 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4978994 | 0.88 | SMN1; SMN2 (0.72) | MCHR1EPHX1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL4981939 | 0.86 | EPHX1 (0.71) | MCHR1EPHX1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL4983316 | 0.86 | MCHR1 (0.51) | MCHR1EPHX1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL14263114 | 0.86 | DRD4 (0.73) | MCHR1EPHX1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL4979582 | 0.86 | SLC6A5 (0.59) | MCHR1EPHX1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL4981899 | 0.86 | MCHR1 (0.51) | MCHR1EPHX1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL4981951 | 0.85 | MCHR1 (0.56) | MCHR1EPHX1HPGDDRD4SSTR4 | |
| SCHEMBL4980231 | 0.84 | RAB9A (0.74) | MCHR1EPHX1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL4983003 | 0.84 | EPHX1 (0.53) | MCHR1EPHX1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL14263140 | 0.84 | MCHR1 (0.52) | MCHR1EPHX1HPGDRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | HRH3, HRH1, HRH4 | MCHR1 132/4885EPHX1 1415/4885HPGD 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.